Prediction method for end-stage nephropathy cardiovascular and cerebrovascular events based on plasma lipidomics and erythrocyte lipidomics

The invention discloses a method for predicting end-stage nephropathy cardiovascular and cerebrovascular events based on plasma lipidomics and erythrocyte lipidomics, and particularly relates to biomarkers PC42: 6, PC42: 7 and SM d18: 1/14: 0, and the biomarkers further comprise new cardiovascular and cerebrovascular event indexes such as age, gender and dialysis year. The invention provides application of a reagent for detecting the biomarker in preparation of a product for auxiliary diagnosis or prediction of whether end-stage nephropathy is combined with cardiovascular and cerebrovascular diseases, and provides a product for auxiliary diagnosis or prediction of whether end-stage nephropathy is combined with cardiovascular and cerebrovascular diseases. The invention also provides an application and a construction method of a related computer model, and also provides an application of the biomarker in a system for automatic auxiliary diagnosis or prediction of whether end-stage nephropathy is combined with c